
MREO
Mereo BioPharma Group PLC
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.8291
Open
1.770
VWAP
--
Vol
1.20M
Mkt Cap
279.84M
Low
1.750
Amount
--
EV/EBITDA(TTM)
--
Total Shares
152.80M
EV
217.36M
EV/OCF(TTM)
--
P/S(TTM)
--
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Show More
5 Analyst Rating

309.09% Upside
Wall Street analysts forecast MREO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MREO is 7.20 USD with a low forecast of 5.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy

309.09% Upside
Current: 1.760

Low
5.00
Averages
7.20
High
10.00

309.09% Upside
Current: 1.760

Low
5.00
Averages
7.20
High
10.00
Needham
Gil Blum
Buy
downgrade
$7 -> $5
2025-07-10
Reason
Needham
Gil Blum
Price Target
$7 -> $5
2025-07-10
downgrade
Buy
Reason
Needham analyst Gil Blum lowered the firm's price target on Mereo BioPharma to $5 from $7 but keeps a Buy rating on the shares. The company announced that the Phase 3 Orbit study will continue towards a final analysis expected in Q4 after missing on its second interim, and this outcome represents the firm's downside scenario, though Needham's overall view on setrusumab's ultimate likelihood of success remains unchanged, given that about 80% alpha spend is reserved for the final analysis, the analyst tells investors in a research note.
Needham
Gil Blum
Strong Buy
Reiterates
$7
2025-04-09
Reason
Needham
Gil Blum
Price Target
$7
2025-04-09
Reiterates
Strong Buy
Reason
JP Morgan
Priyanka Grover
Buy
Initiates
$7
2025-03-27
Reason
JP Morgan
Priyanka Grover
Price Target
$7
2025-03-27
Initiates
Buy
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$7
2025-03-26
Reason
Needham
Gil Blum
Price Target
$7
2025-03-26
Reiterates
Strong Buy
Reason
Cantor Fitzgerald
Kristen Kluska
Buy
Reiterates
$7
2025-03-18
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$7
2025-03-18
Reiterates
Buy
Reason
Group Dinner Meeting to be held in London, England on March 13 hosted by Cantor Fitzgerald.
Needham
Gil Blum
Strong Buy
Reiterates
$7
2025-01-13
Reason
Needham
Gil Blum
Price Target
$7
2025-01-13
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Mereo BioPharma Group PLC (MREO.O) is -99.22, compared to its 5-year average forward P/E of -77.41. For a more detailed relative valuation and DCF analysis to assess Mereo BioPharma Group PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-77.41
Current PE
-99.22
Overvalued PE
25.86
Undervalued PE
-180.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.21
Current EV/EBITDA
-17.36
Overvalued EV/EBITDA
3.61
Undervalued EV/EBITDA
-8.04
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
8.80
Current PS
11.65
Overvalued PS
18.53
Undervalued PS
-0.93
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
+13.15%
-11.20M
Operating Profit
FY2025Q1
YoY :
+43.97%
-12.89M
Net Income after Tax
FY2025Q1
YoY :
+100.00%
-0.02
EPS - Diluted
FY2025Q1
YoY :
-0.48%
-8.65M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
N/A
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 188.03% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
1.8M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
308.6K
Volume
2
6-9
Months
60.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
1
250.0K
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
269.8K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 188.03% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
1.8M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MREO News & Events
Events Timeline
2025-07-09 (ET)
2025-07-09
16:16:37
Ultragenyx, Mereo BioPharma receive DMC recommendation to continue Orbit study

2025-05-13 (ET)
2025-05-13
07:40:02
Mereo BioPharma sees cash runway into 2027

2025-05-13
07:39:34
Mereo BioPharma reports Q1 EPS (2c), consensus (1c)

Sign Up For More Events
Sign Up For More Events
News
4.0
07-28BenzingaUltragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
7.0
07-28GlobenewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
7.0
07-27PRnewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Sign Up For More News
People Also Watch

MYE
Myers Industries Inc
15.070
USD
-0.79%

CVGW
Calavo Growers Inc
26.310
USD
-0.04%

WDH
Waterdrop Inc
1.890
USD
-7.35%

SMC
Summit Midstream Corp
25.550
USD
+0.47%

FC
Franklin Covey Co
20.220
USD
-0.69%

PNNT
Pennantpark Investment Corp
7.310
USD
-1.75%

HPP
Hudson Pacific Properties Inc
2.420
USD
-3.97%

API
Agora Inc
3.940
USD
-1.50%

KROS
Keros Therapeutics Inc
14.510
USD
+0.35%

CVRX
CVRx Inc
8.430
USD
+1.08%
FAQ

What is Mereo BioPharma Group PLC (MREO) stock price today?
The current price of MREO is 1.76 USD — it has increased 0 % in the last trading day.

What is Mereo BioPharma Group PLC (MREO)'s business?

What is the price predicton of MREO Stock?

What is Mereo BioPharma Group PLC (MREO)'s revenue for the last quarter?

What is Mereo BioPharma Group PLC (MREO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Mereo BioPharma Group PLC (MREO)'s fundamentals?

How many employees does Mereo BioPharma Group PLC (MREO). have?
